The research focuses on a protein called "Slowpoke" that promotes communication between neurons and the tumour
Read moreThe strategy developed by the IR Sant Pau team uses multivalent protein nanoconjugates capable of specifically recognizing cells that express CXCR4. These nanoparticles act as precision delivery vehic...
Read moreA study published today in Nature Communications reveals a new way of measuring that editing process, known as splicing, directly. It is the first time scientists have been able to get a clear view of...
Read moreThe absence of a protein, the kinase IKKα, enables tumor cells to cluster and survive during dissemination
Read more3PBIOVIAN and the Colombia INC has signed a contract to carry out the development of a biosimilar monoclonal antibody (mAb) for an oncology indication, marking the first biosimilar mAb to be developed...
Read moreA multi‑country oncology study regained momentum through structured transition planning, seamless cross‑functional collaboration and decisive operational oversight, regulatory recovery, and discip...
Read moreEl estudio del grupo de investigación de Metabolismo y Cáncer (IDIBGI-ICO) propone que conocer la flexibilidad mitocondrial y los niveles de SASP del tumor antes del tratamiento puede guiar su elimi...
Read moreEl Dr. Endika Torres-Urtizberea diseña en su tesis nuevos fármacos basados en pirido[2,3-d]pirimidinas que atacan simultáneamente las proteínas FGFR2 e IGF1R para evitar que las células tumorales...
Read moreThe work is based on real clinical practice data and provides new evidence on the clinical activity of immunotherapy and tyrosine kinase inhibitors in the control of this disease.
Read moreLa incubadora de alta tecnología alcanza el 85 % de ocupación en sus primeros siete meses de vida y se posiciona como un referente en la retención de talento científico.
Read moreSe trata de un antiangiogénico, fármaco que impide la formación de nuevos vasos sanguíneos, que alimentan el tumor
Read moreEl trabajo revela que la presencia de múltiples copias del gen MDM4 es un indicador fiable de riesgo de recaída en pacientes con carcinoma endometrio de bajo grado y en estadios tempranos.
Read more